Pre-Emptive OCT-Guided Angioplasty of Vulnerable Intermediate Coronary Lesions: Results from the Prematurely Halted PECTUS-Trial
Journal of Interventional Cardiology · 03.12.2020 · 2020 · 1-8
DOI: 10.1155/2020/8821525 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Interventional Cardiology, erschienen am 03.12.2020. Verfasst von Jan-Quinten Mol und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Radboud University Medical Center, Nijmegen, Netherlands. Hauptthemen laut MEDLINE: Absorbable Implants, Coronary Vessels, Myocardial Infarction, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Abbott Vascular, Health~Holland.
Abstract (Originalsprache)
Objectives
To assess the safety and efficacy of pre-emptive treatment of optical coherence tomography- (OCT-) derived vulnerable, non-flow-limiting, non-culprit lesions in patients with myocardial infarction (MI).
Background
Intracoronary imaging with OCT can aid in the decision to treat non-flow-limiting lesions by identifying vulnerable plaques. Pre-emptive treatment of these lesions might improve patient outcome by “sealing” these plaques. Bioresorbable vascular scaffolds (BVS) have theoretical benefit for this treatment because they dissolve completely over time.
Methods
In patients presenting with MI, non-culprit lesions with a fractional flow reserve ≥0.8 were imaged with OCT. Vulnerable plaques were randomised to either percutaneous coronary intervention (PCI) with bioresorbable vascular scaffold (BVS) placement or optimal medicinal therapy (OMT). The primary outcome was a composite of all-cause mortality, non-fatal MI, and unplanned revascularisation at 1-year follow-up.
Results
The trial was stopped prematurely after retraction from the market of the Absorb BVS. At that time, a total of 34 patients were randomised. At two years, the composite endpoint occurred 3 times (18.8%) in the BVS group and 1 time (6.3%) in the OMT group. Apart from one elective PCI for stable angina in the OMT group, no target lesions in any group were revascularised.
Conclusions
Pre-emptive stenting of vulnerable plaques had no evident benefit compared to conservative treatment. However, due to the low number of included patients, no definite conclusions could be drawn. Identifying and potentially treating vulnerable plaques remains an important target for future research. This trial is registered under https://www.trialregister.nl/trial/NL4177 on 08-12-2015.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Cardiology, Radboud University Medical Center, Nijmegen, Netherlands.
- Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
ORCID-Profile: Jan-Quinten Mol, Niels van Royen
Förderung
- Abbott Vascular
- Health~Holland
Zitieren
APA
Mol, J. Q., Bom, M. J., Damman, P., Knaapen, P., & van Royen, N. (2020). Pre-Emptive OCT-Guided Angioplasty of Vulnerable Intermediate Coronary Lesions: Results from the Prematurely Halted PECTUS-Trial. Journal of Interventional Cardiology, 2020, 1-8. https://doi.org/10.1155/2020/8821525
Vancouver
Mol JQ, Bom MJ, Damman P, Knaapen P, van Royen N. Pre-Emptive OCT-Guided Angioplasty of Vulnerable Intermediate Coronary Lesions: Results from the Prematurely Halted PECTUS-Trial. Journal of Interventional Cardiology. 2020;2020:1-8. doi:10.1155/2020/8821525
BibTeX
@article{Mol2020,
author = {Mol, Jan-Quinten and Bom, Michiel J and Damman, Peter and Knaapen, Paul and van Royen, Niels},
title = {Pre-Emptive OCT-Guided Angioplasty of Vulnerable Intermediate Coronary Lesions: Results from the Prematurely Halted PECTUS-Trial},
journal = {Journal of Interventional Cardiology},
year = {2020},
volume = {2020},
pages = {1--8},
doi = {10.1155/2020/8821525}
}
EUVIMED